Login to Your Account



Baxter, Coherus in Potential $246M Biosimilar Deal

By Marie Powers
Staff Writer

Wednesday, September 4, 2013
Coherus Biosciences Inc. expanded the horizons for its biosimilar product for Enbrel (etanercept, Amgen Inc.) by inking a potential $246 million deal giving Baxter International Inc. rights to the drug in Europe, Canada, Brazil and other undisclosed markets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription